Cardiovascular Disease Risk in Women With Endometriosis
NCT03746535
· ctgov
completed
phase early-phase-1
- Enrollment
- 21
- Start
- 2022-07-01
- Completion
- 2025-05-27
- Last updated
- 2026-10-16
- Has results
- True
- Countries
- United States
Conditions
Tagged with
Interventions
-
Elagolix
DRUG
Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
Eligibility criteria
Inclusion Criteria:
* Young women between the ages of 18 and 45 years (Controls);
* Young women between the ages of 18 and 45 years with endometriosis.
Exclusion Criteria:
* Subjects who smoke
* Subjects who have diabetes,
* Subjects with sleep apnea or BP\>140/90 will be excluded.
* Women with endometriosis and severe acute pain requiring immediate treatment will be excluded.
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of ClinicalTrials.gov / U.S. National Library of Medicine
Courtesy of ClinicalTrials.gov / U.S. National Library of Medicine